Fluorine-18 labeling of ML04 - Presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 49, Issue 6, 2006, Pages 533-543

  Dissoki, Samar ^a   Laky, Desideriu ^a   Mishani, Eyal ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cancer; EGFR; PET; 18F

Indexed keywords

DIAGNOSIS; FLUORINE;

CANCER; EGFR; FLUORINE-18; GEFITINIB; IN-VIVO; LABELINGS; OVEREXPRESSIONS; RADIOSYNTHESIS; VIVO STUDIES; [18F];

DISEASES;

BIOLOGICAL MARKER; CARBON 11; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORINE 18; GEFITINIB; ML04 C 11; ML04 F 18; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; IN VIVO STUDY; ISOTOPE LABELING; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOCHEMISTRY; RADIOISOTOPE DECAY;

ANIMALIA;

EID: 33745599854     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.1071     Document Type: Article

References (20)

1. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Ann Oncol 1997; 8: 1197-1206.
2. Ritter CA, Artega CL. Sem Oncol 2003; 30: 993-1011.
3. Raymond E, Faivre S, Armand JP. Drugs 2000; 60: 15-23 (discussion 41-2).
4. Salomon DS, Brandt R, Ciardiello F, Normanno N. Crit Rev Oncol Hematol 1995; 19: 183-232.
5. Rae JM, Lippman ME. Breast Cancer Res Treat 2004; 83: 99-107.
6. Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben-Daniel R, Levitzki A. J Med Chem 2005; 48(16): 5337-5348.
7. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. Oncologist 2003; 8: 303-306.
8. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. J Clin Oncol 2005; 23(28): 6813-6816.
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. Science 2004; 304: 1497-1500.
10. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. N Engl J Med 2004; 350: 2129-2139.
11. Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, Ben-David I, Levitzki A, Shaul M. J Nucl Med Biol 2004; 31: 469-476.
12. VanBrocklin HF, Dorff PN, Vasdev N, O'Neil JP, Nandanan E, Gibbs AR. J Label Compd Radiopharm 2003; 46: S117.
13. Ackermann U, Tochon-Dabguy H, Nice E, Nerrie M, Young K, Sachinidis J, Scott A. J Label Compd Radiopharm 2003; 46: S118.
14. Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, Mishani E. Biol Med Chem 2004; 12: 3421-3429.
15. Ortu G, Ben-David I, Rozen Y, Freedman NMT, Chisin R, Levitzki A, Mishani E. Int J Cancer 2002; 101(4): 360-370.
16. Seimbille Y, Phelps ME, Czernin J, Silverman DHS. J Label Compd Radiopharm 2005; 48: 829-843.
17. Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, Chisin R, Levitzki A, Mishani E. Nucl Med Biol 2001; 28: 359-374.
18. Vasdev N, Dorff PN, Gibbs AR, Nandanan E, Reid LM, O'Neil JP, VanBrocklin HF. J Label Compd Radiopharm 2005; 48: 109-115.
19. Acheson RM, Taylor GA, Tomlinson ML. J Chem Soc 1958; 3750-3752.
20. Tsou H-R, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlance R, Davis R, Koehn FE, Greenberger LM, Wang Y-F, Wissner A. J Med Chem 2001; 44: 2719-2734.